Document Classification

Section Type: RESULTS

Text: Observed survival up to 36 months was reported as a Kaplan-Meier estimate in three cohorts : (1) In 169 PPH patients treated with first-line bosentan, 1 - and 2-year survival was 96 % and 89 %, respectively, vs. predicted untreated survival at 1 and 2 years of 69 % and 57 %, respectively ; (2) in 50 patients with PAH associated with SSc (PAH-SSc), 1 -, 2 - and 3-year survival was 82 %, 67 % and 64 %, respectively, vs. approximately 45 %, approximately 35 % and approximately 28 %, respectively, from registry data of untreated PAH-SSc patients ; and (3) in 139 PPH patients in WHO functional class III, 1 - and 2-year survival was 97 % and 91 %, respectively, vs. 91 % and 84 % in a historical cohort of 346 patients treated with epoprostenol in five major referral centres.